Individual patient data subgroup analysis of sources of heterogeneity regarding the proportion of stage I cancers in CT lung cancer screening studies.

Proportion of study participants disaggregated by the type of cancers and the country in which they received treatment.

Mary W. Wangai (13840333)
Frederick K. Wangai (6321347)
Francis Njiri (188361)
Enan N. Wangai (13840336)
Paul Wangai (13840339)
Catherine Nyongesa (13840342)
John Kinuthia (188338)

September 2022

Proportion of study participants disaggregated by the type of cancers and the country in which they ...

Distribution of lung cancer cases and controls according to demographic and histology variables.

Pierre P. Massion (221783)
Yong Zou (372288)
Hasmet Uner (372289)
Porntip Kiatsimkul (372290)
Holly J. Wolf (372291)
Anna E. Baron (372292)
Tim Byers (284371)
Steinn Jonsson (372293)
Stephen Lam (61568)
Fred R. Hirsch (372294)
York E. Miller (359068)
Wilbur A. Franklin (372295)
Marileila Varella-Garcia (258433)

February 2013

Distribution of lung cancer cases and controls according to demographic and histology variables.<...

Summary of heterogeneity and subgroup analysis based on study year, sample size and study regions.

Melkie Dagnaw (16715422)
Bihonegn Wodajnew (16715425)
Tsegaw Fentie (4676623)
Atsede Solomon (16715428)
Firdyawukal Abuhay (16715431)
Nigist Bizu (16715434)
Ahmed Abi (16715437)

July 2023

Summary of heterogeneity and subgroup analysis based on study year, sample size and study regions.</...

Study level subgroup analysis of sources of heterogeneity regarding the proportion of stage I cancers in CT lung cancer screening studies.

Zixing Wang (48767)
Yaoda Hu (3220251)
Yuyan Wang (283747)
Wei Han (151406)
Lei Wang (6656)
Fang Xue (2589934)
Xin Sui (211430)
Wei Song (30780)
Ruihong Shi (3220254)
Jingmei Jiang (269026)

October 2016

Study level subgroup analysis of sources of heterogeneity regarding the proportion of stage I can...

The results of subgroup analyses performed according to the potential sources of heterogeneity.

Peng Wang (34436)
Huifang Liu (792239)
Ting Jiang (792240)
Julun Yang (792241)

September 2015

Abbreviations: No. of datasets, Number of datasets (papers); MDS, Myelodysplastic Syndrome...

Subgroups analysis based on histological cancer type, omitting one heterogeneous study.

Antonella Agodi (638417)
Martina Barchitta (638414)
Annalisa Quattrocchi (638415)
Andrea Maugeri (638416)
Manlio Vinciguerra (287299)

August 2015

(A) Squamous Cell Carcinoma (SCC) subgroup analysis, based on the random effects model. (B) Adeno...

Subgroups of patients participating in immunohistochemistry, microarray analysis and PCR validation with the number of samples and mean age values.

Katalin Leiszter (123735)
Orsolya Galamb (123720)
Ferenc Sipos (123723)
Tibor Krenács (123730)
Gábor Veres (298799)
Barnabás Wichmann (123721)
Alexandra Kalmár (123738)
Árpád V. Patai (132272)
Kinga Tóth (123732)
Gábor Valcz (466332)
Béla Molnár (123745)
Zsolt Tulassay (123741)

October 2013

Subgroups of patients participating in immunohistochemistry, microarray analysis and PCR validati...

Subgroup analyses for association between HCC surveillance and early detection, curative treatment rates, and survival.

Amit G. Singal (545537)
Anjana Pillai (545538)
Jasmin Tiro (545539)

April 2014

Subgroup analyses for association between HCC surveillance and early detection, curative treatmen...

Subgroup analysis for high versus low PUFA intake for lung cancer (A); Subgroup analysis for per 5 g/day increment in PUFA intake for lung cancer (B).

Yu-Fei Zhang (548799)
Jian Lu (51707)
Fei-Fei Yu (540494)
Hong-Fang Gao (548800)
Yu-Hao Zhou (156711)

June 2014

Subgroup analysis for high versus low PUFA intake for lung cancer (A); Subgroup analysis for per ...

Assessment of clinical heterogeneity: subgroup analysis for order of treatment.

Anat Fisher (618829)
Ken Bassett (372058)
Gautam Goel (457889)
Dana Stanely (3387761)
M. Alan Brookhart (459340)
Hugh R. Freeman (3387758)
James M. Wright (372059)
Colin R. Dormuth (372054)

December 2016

Assessment of clinical heterogeneity: subgroup analysis for order of treatment.</p

Heterogeneity of patients in clinical trials: Subgroup analysis and covariate adjustment in cardiovascular and neurosurgical trials

Hernández, Adrián

February 2006

textabstractRandomized clinical trials (RCTs) are essential to evaluate the usefulness of treatment...

Subgroup analysis of lung cancer for folate intake versus the lowest intake.

Yu-Fei Zhang (548799)
Li Zhou (54356)
Hong-Wei Zhang (2275558)
An-Ji Hou (383570)
Hong-Fang Gao (548800)
Yu-Hao Zhou (156711)

April 2014

Subgroup analysis of lung cancer for folate intake versus the lowest intake.</p

Demographic data for lung cancer patients and healthy controls in the current study.

Fang Wang (105926)
Jian Xu (31545)
Quan Zhu (53796)
Xuejun Qin (46445)
Yan Cao (482880)
Jiangfang Lou (482881)
Yuqiao Xu (482882)
Xing Ke (482883)
Qing Li (84975)
Erfu Xie (482884)
Lixia Zhang (187984)
Ruihong Sun (327787)
Liang Chen (73736)
Bingliang Fang (184412)
Shiyang Pan (208568)

November 2013

Demographic data for lung cancer patients and healthy controls in the current study.</p

Clinical and demographic profile of patients as per the etiologic subgroups.

Patil Anuja (4778787)
Vishnu Venugopalan (4778790)
Naheed Darakhshan (4778784)
Pandit Awadh (4778802)
Vinny Wilson (4778799)
Goyal Manoj (4778793)
Modi Manish (4778781)
Lal Vivek (4778796)

January 2018

Clinical and demographic profile of patients as per the etiologic subgroups.</p

Demographic, tumor, socio-economic characteristic and treatment modes for lung cancer patients with stages I, II, IIIA, IIIB, and IV.

Igor Akushevich (163135)
Konstantin Arbeev (718418)
Julia Kravchenko (163129)
Mark Berry (310183)

April 2015

*—quintiles of distribution of entire patient groups, i.e., for all stages (0—lowest, 4—highest)<...

Proportion of study participants disaggregated by the type of cancers and the country in which they received treatment.

Mary W. Wangai (13840333)
Frederick K. Wangai (6321347)
Francis Njiri (188361)
Enan N. Wangai (13840336)
Paul Wangai (13840339)
Catherine Nyongesa (13840342)
John Kinuthia (188338)

September 2022

Proportion of study participants disaggregated by the type of cancers and the country in which they ...

Distribution of lung cancer cases and controls according to demographic and histology variables.

Pierre P. Massion (221783)
Yong Zou (372288)
Hasmet Uner (372289)
Porntip Kiatsimkul (372290)
Holly J. Wolf (372291)
Anna E. Baron (372292)
Tim Byers (284371)
Steinn Jonsson (372293)
Stephen Lam (61568)
Fred R. Hirsch (372294)
York E. Miller (359068)
Wilbur A. Franklin (372295)
Marileila Varella-Garcia (258433)

February 2013

Distribution of lung cancer cases and controls according to demographic and histology variables.<...

Summary of heterogeneity and subgroup analysis based on study year, sample size and study regions.

Melkie Dagnaw (16715422)
Bihonegn Wodajnew (16715425)
Tsegaw Fentie (4676623)
Atsede Solomon (16715428)
Firdyawukal Abuhay (16715431)
Nigist Bizu (16715434)
Ahmed Abi (16715437)

July 2023

Summary of heterogeneity and subgroup analysis based on study year, sample size and study regions.</...

Study level subgroup analysis of sources of heterogeneity regarding the proportion of stage I cancers in CT lung cancer screening studies.

Zixing Wang (48767)
Yaoda Hu (3220251)
Yuyan Wang (283747)
Wei Han (151406)
Lei Wang (6656)
Fang Xue (2589934)
Xin Sui (211430)
Wei Song (30780)
Ruihong Shi (3220254)
Jingmei Jiang (269026)

October 2016

Study level subgroup analysis of sources of heterogeneity regarding the proportion of stage I can...

The results of subgroup analyses performed according to the potential sources of heterogeneity.

Peng Wang (34436)
Huifang Liu (792239)
Ting Jiang (792240)
Julun Yang (792241)

September 2015

Abbreviations: No. of datasets, Number of datasets (papers); MDS, Myelodysplastic Syndrome...

Subgroups analysis based on histological cancer type, omitting one heterogeneous study.

Antonella Agodi (638417)
Martina Barchitta (638414)
Annalisa Quattrocchi (638415)
Andrea Maugeri (638416)
Manlio Vinciguerra (287299)

August 2015

(A) Squamous Cell Carcinoma (SCC) subgroup analysis, based on the random effects model. (B) Adeno...

Subgroups of patients participating in immunohistochemistry, microarray analysis and PCR validation with the number of samples and mean age values.

Katalin Leiszter (123735)
Orsolya Galamb (123720)
Ferenc Sipos (123723)
Tibor Krenács (123730)
Gábor Veres (298799)
Barnabás Wichmann (123721)
Alexandra Kalmár (123738)
Árpád V. Patai (132272)
Kinga Tóth (123732)
Gábor Valcz (466332)
Béla Molnár (123745)
Zsolt Tulassay (123741)

October 2013

Subgroups of patients participating in immunohistochemistry, microarray analysis and PCR validati...

Subgroup analyses for association between HCC surveillance and early detection, curative treatment rates, and survival.

Amit G. Singal (545537)
Anjana Pillai (545538)
Jasmin Tiro (545539)

April 2014

Subgroup analyses for association between HCC surveillance and early detection, curative treatmen...

Subgroup analysis for high versus low PUFA intake for lung cancer (A); Subgroup analysis for per 5 g/day increment in PUFA intake for lung cancer (B).

Yu-Fei Zhang (548799)
Jian Lu (51707)
Fei-Fei Yu (540494)
Hong-Fang Gao (548800)
Yu-Hao Zhou (156711)

June 2014

Subgroup analysis for high versus low PUFA intake for lung cancer (A); Subgroup analysis for per ...

Assessment of clinical heterogeneity: subgroup analysis for order of treatment.

Anat Fisher (618829)
Ken Bassett (372058)
Gautam Goel (457889)
Dana Stanely (3387761)
M. Alan Brookhart (459340)
Hugh R. Freeman (3387758)
James M. Wright (372059)
Colin R. Dormuth (372054)

December 2016

Assessment of clinical heterogeneity: subgroup analysis for order of treatment.</p

Heterogeneity of patients in clinical trials: Subgroup analysis and covariate adjustment in cardiovascular and neurosurgical trials

Hernández, Adrián

February 2006

textabstractRandomized clinical trials (RCTs) are essential to evaluate the usefulness of treatment...

Subgroup analysis of lung cancer for folate intake versus the lowest intake.

Yu-Fei Zhang (548799)
Li Zhou (54356)
Hong-Wei Zhang (2275558)
An-Ji Hou (383570)
Hong-Fang Gao (548800)
Yu-Hao Zhou (156711)

April 2014

Subgroup analysis of lung cancer for folate intake versus the lowest intake.</p

Demographic data for lung cancer patients and healthy controls in the current study.

Fang Wang (105926)
Jian Xu (31545)
Quan Zhu (53796)
Xuejun Qin (46445)
Yan Cao (482880)
Jiangfang Lou (482881)
Yuqiao Xu (482882)
Xing Ke (482883)
Qing Li (84975)
Erfu Xie (482884)
Lixia Zhang (187984)
Ruihong Sun (327787)
Liang Chen (73736)
Bingliang Fang (184412)
Shiyang Pan (208568)

November 2013

Demographic data for lung cancer patients and healthy controls in the current study.</p

Clinical and demographic profile of patients as per the etiologic subgroups.

Patil Anuja (4778787)
Vishnu Venugopalan (4778790)
Naheed Darakhshan (4778784)
Pandit Awadh (4778802)
Vinny Wilson (4778799)
Goyal Manoj (4778793)
Modi Manish (4778781)
Lal Vivek (4778796)

January 2018

Clinical and demographic profile of patients as per the etiologic subgroups.</p

Demographic, tumor, socio-economic characteristic and treatment modes for lung cancer patients with stages I, II, IIIA, IIIB, and IV.

Igor Akushevich (163135)
Konstantin Arbeev (718418)
Julia Kravchenko (163129)
Mark Berry (310183)

April 2015

*—quintiles of distribution of entire patient groups, i.e., for all stages (0—lowest, 4—highest)<...

Proportion of study participants disaggregated by the type of cancers and the country in which they received treatment.

Mary W. Wangai (13840333)
Frederick K. Wangai (6321347)
Francis Njiri (188361)
Enan N. Wangai (13840336)
Paul Wangai (13840339)
Catherine Nyongesa (13840342)
John Kinuthia (188338)

September 2022

Proportion of study participants disaggregated by the type of cancers and the country in which they ...

Distribution of lung cancer cases and controls according to demographic and histology variables.

Pierre P. Massion (221783)
Yong Zou (372288)
Hasmet Uner (372289)
Porntip Kiatsimkul (372290)
Holly J. Wolf (372291)
Anna E. Baron (372292)
Tim Byers (284371)
Steinn Jonsson (372293)
Stephen Lam (61568)
Fred R. Hirsch (372294)
York E. Miller (359068)
Wilbur A. Franklin (372295)
Marileila Varella-Garcia (258433)

February 2013

Distribution of lung cancer cases and controls according to demographic and histology variables.<...

Summary of heterogeneity and subgroup analysis based on study year, sample size and study regions.

Melkie Dagnaw (16715422)
Bihonegn Wodajnew (16715425)
Tsegaw Fentie (4676623)
Atsede Solomon (16715428)
Firdyawukal Abuhay (16715431)
Nigist Bizu (16715434)
Ahmed Abi (16715437)

July 2023

Summary of heterogeneity and subgroup analysis based on study year, sample size and study regions.</...

Individual patient data subgroup analysis of sources of heterogeneity regarding the proportion of stage I cancers in CT lung cancer screening studies.

Abstract

Extracted data

Individual patient data subgroup analysis of sources of heterogeneity regarding the proportion of stage I cancers in CT lung cancer screening studies.

Abstract

Extracted data

Related items

Related items